# Aristotelis Nastos

> Aristotelis Nastos is a seed investor at NRW.BANK (Cologne) backing Biotechnology and Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [NRW.BANK](https://shizune.co/investors/profile/nrw-bank)
- Location: Cologne, Germany
- Total investments: 3
- Last investment: Mar 2026
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/aristotelis-nastos-568040b9

Aristotelis Nastos is a seed investor at NRW.BANK in Cologne focused on Biotechnology and Health Care. Dr. Aristotelis Nastos - Head of Life Sciences & Cleantech @ NRW.BANK

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 100% |
| Health Care | 2 | 67% |
| Medical | 1 | 33% |
| Chemical | 1 | 33% |
| Oncology | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |
| Venture - Series Unknown | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| iDEL Therapeutics | iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism. | $10.4M | Seed | Mar 17, 2026 |  |
| T-CURX | T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designedto improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care. | $20M | Series A | Dec 17, 2025 |  |
| CEVEC Pharmaceuticals | CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system.CAP-Go enables the production of proteins “beyond antibodies”. Complex, glycosylated proteins represent a significant portion of the human proteome and are notoriously difficult to express in conventional cell lines such asCHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns. |  | Venture - Series Unknown | Jul 27, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Bayern Kapital](https://shizune.co/investors/profile/bayern-kapital) — VC Fund, 1 deal together
- [Gruenderfonds Ruhr](https://shizune.co/investors/profile/gruenderfonds-ruhr) — VC Fund, 1 deal together
- [HighLight Capital](https://shizune.co/investors/profile/highlight-capital) — VC Fund, 1 deal together
- [i&i Biotech Fund](https://shizune.co/investors/profile/i-i-biotech-fund) — VC Fund, 1 deal together
- [KHAN Technology Transfer Fund](https://shizune.co/investors/profile/khan-technology-transfer-fund) — VC Fund, 1 deal together
- [NRW.Venture](https://shizune.co/investors/profile/nrw-venture) — VC Fund, 1 deal together

## About NRW.BANK

VC Fund · Düsseldorf, Germany

NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the FederalRepublic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.

5 contacts available at NRW.BANK.

| Name | Title | Profile |
| --- | --- | --- |
| Aristotelis Nastos | Head of Life Sciences & Cleantech | https://shizune.co/investors/profile/dr-aristotelis-nastos |
| Claas Heise | Executive Director | https://shizune.co/investors/profile/claas-heise |
| Dietrich Suhlrie | Member of the Managing Board | https://shizune.co/investors/profile/dietrich-suhlrie |
| Eckhard Forst | Chairman of the Managing Board | https://shizune.co/investors/profile/eckhard-forst |
| Gabriele Pantring | Member of the Managing Board | https://shizune.co/investors/profile/gabriele-pantring |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Aristotelis Nastos invest in?

Aristotelis Nastos invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Aristotelis Nastos last invest?

The most recent investment recorded for Aristotelis Nastos closed in Mar 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co